Comprehensive Strategy to Decolonize Methicillin-resistant Staphylococcus Aureus (MRSA) in the Outpatient Setting


The purpose of this study is to determine the effectiveness of topical and oral antibiotics in eliminating carriage of methicillin-resistant Staphylococcus aureus (MRSA) among those living in the community. We hypothesize that a greater proportion of those who receive intervention will eliminate MRSA carriage compared to those who do not receive any intervention.

Full Title of Study: “Comprehensive Strategy to Decolonize Methicillin-resistant Staphylococcus Aureus in the Outpatient Setting: a Randomized Controlled Study”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: April 2012


  • Drug: pharmacological decolonization treatment
    • Chlorhexidine gluconate 4% body scrub and 2% shampoo daily PLUS mupirocin 2%, fusidic acid 2%, or chlorhexidine gluconate 0.2% intranasally bid PLUS trimethoprim-sulfamethoxazole 160/800mg po bid or doxycycline 100mg po bid all for 7 days
  • Behavioral: Education
    • No pharmacological decolonization treatment but given education regarding personal hygiene and environmental cleaning

Arms, Groups and Cohorts

  • Active Comparator: decolonization treatment
    • topical antiseptic, intranasal antimicrobial, and oral antimicrobial that have activity against MRSA in addition to education regarding personal hygiene and environmental cleaning
  • Other: education
    • No decolonization treatment in addition to education regarding personal hygiene and environmental cleaning

Clinical Trial Outcome Measures

Primary Measures

  • Eradication of MRSA carriage
    • Time Frame: 90 days after randomization

Secondary Measures

  • Occurrence of MRSA infection
    • Time Frame: Within 6 months of randomization

Participating in This Clinical Trial

Inclusion Criteria

  • Prior MRSA infection (i.e index case)
  • Identified as being colonized with MRSA on initial screen

Exclusion Criteria

  • Are pregnant or breastfeeding.
  • Have indwelling catheters.
  • Received prior decolonization treatment within last 6 months of enrollment.
  • Have allergy to study medication.
  • Are colonized with MRSA strain resistant to study medication.
  • Have active infection requiring systemic antimicrobials.
  • Are household contacts to index case.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Joseph Kim
  • Collaborator
    • Alberta Health Services
  • Provider of Information About this Clinical Study
    • Sponsor-Investigator: Joseph Kim, Clinical Assistant Professor – University of Calgary
  • Overall Official(s)
    • Thomas J Louie, MD, Principal Investigator, University of Calgary

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.